Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): A tissue microarray study (TMA)

Prostate

Volumn 70, Issue 13, 2010, Pages 1429-1436

  Evren, Sevan ^a   Dermen, Arthur ^a   Lockwood, Gina ^b   Fleshner, Neil ^a   Sweet, Joan ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Canadian Partnership Against Cancer   (Canada)

Author keywords

Immunohistochemistry; MTOR; MTORC1; RAPTOR; Tissue microarray

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN P70; PROTEIN S6; PROTEIN SUBUNIT; RIBOSOME PROTEIN; S6 KINASE; MTORC1 PROTEIN, HUMAN; PROTEIN; PROTEIN KINASE B; RAPTOR PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GRADING; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ADENOCARCINOMA; ADULT; CHI SQUARE DISTRIBUTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 77956625396     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21178     Document Type: Article

References (34)

1. Jemal A, Thomas A, Murray T, Thun M,. Cancer statistics, 2002. Cancer J Clin 2002; 52: 23 -47.
2. Prange W, Erbersdobler A, Hammerer P, Graefen M, Hautmann SH, Hautmann RE, Huland RP,. Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. Urology 2001; 57 (30): 486 -490.
3. Garnick MB,. Prostate cancer: Screening, diagnosis, and management. Ann Intern Med 1993; 118 (10): 804 -818.
4. Yashimoto M, Cutz J, Nuin PA, Joshua AM, Bayani J, Evan AJ, Zielenksa M, Squire JA,. Interphase FSH analysis of PTEN in histolofical sections show genoimic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128 -137.
5. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J,. Rheb binds and regulates Mtor kinase. Cell Biol 2005; 15: 702 -713.
6. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM,. mTOR interacts with RAPTOR to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163 -175.
7. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K,. Raptor, a binding partner of target ofrapamycin (TOR), mediates TOR action. Cell 2002; 110: 177 -189.
8. Loewwith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN,. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457 -468.
9. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM,. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296 -1302.
10. Isotani S, Hara K, Tokunga C, Inoue H, Avruch J, Yonezawa K,. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 s6 kinase alpha in vitro. J Biol Chem 1999; 274: 34493 -34498.
11. Gingras A, Raught B, Sonenberg N,. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807 -826.
12. Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O,. Amino acid-induced translation of TOP mRNAs is fully dependenton phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol 2001; 21 (24): 8671 -8683.
13. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN,. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 11: 1122 -1128.
14. Faivre S, Kroemer G, Raymond E,. Current development of mTOR inhibitors as anticancer agents. Nature Rev Drug Discov 2006; 5: 671 -688.
15. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL,. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95: 1148 -1154.
16. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA,. Increased AKT S478 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumoral cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009; 8: 742 -753.
17. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR,. Activation of AKT and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65 (16): 7052 -7058.
18. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D,. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008; 111 (1): 379 -382.
19. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ,. Rapamycin induced feedback activation of AKT signaling through an IGF-1R-dependant mechanism. Oncogene 2007; 26: 1932 -1940.
20. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N,. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500 -1508.
21. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A,. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 10: 1533 -1540.
22. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP,. Inhibition of the MTORC1 pathway leads to MAPK pathway activation through a PI3K-dependant feedback loop in human cancer. J Clin Invest 2008; 118: 3065 -3074.
23. Brown RE, Zotalis G, Zhang PL, Zhao B,. Morphoproteomic conformation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 2008; 1: 333 -342.
24. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C,. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118 (9): 3051 -3064.
25. Kononen J, Bubendorf L, Kallionimeni A, Brlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni O,. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nature Med 1998; 4: 844 -847.
26. Stewart J, Fleshner N, Cole H, Sweet J,. Comparison of annexin II, p63 and a-methylacyl-CoA racemase immunoreactivity in prostatic tissue: A tissue microarray study. J Clin Pathol 2007; 60: 773 -780.
27. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG, Jr,. Regulation of mTOR function in response to hypoxia by REDD1 and TSC1/TSC2 tumor suppressor complex. Gene Dev 2004; 18: 2893 -2904.
28. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW,. Hypoxia regulates TSC1/2-Mtor signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Gene Dev 2008; 22: 239 -251.
29. Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, Stobbe C, Hanks GE,. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age an Eppendorf pO2 study. Cancer 2000; 89 (9): 2018 -2024.
30. Zhong H, Agani F, Baccala AA, Laughner E,., Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL,. Increased expression of hypoxia inducible factor-1 a in a rat and human prostate cancer. Cancer Res 1998; 58: 5280 -5284.
31. 2 study. Am J Clin Oncol 2001; 24 (5): 458 -461.
32. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI,. Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. Clin Cancer Res 2002; 1168 (8): 1168 -1171.
33. Treins C, Warne PH, Magnuson MA, Pende M, Downward J,. Rictor is a novel target of p70 S6 kinase-1. Oncogene 2009; 1 -14.
34. Ali SM, Sabatini DM,. Structure of s6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 2005; 280 (20): 19445 -19448.